Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Neoplasms of the CNS

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 64 articles:
HTML format



Single Articles


    February 2024
  1. KOCHANEK C, Gilde C, Zimmer L, Ugurel S, et al
    Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Eur J Cancer. 2024;198:113508.
    PubMed     Abstract available


    January 2024
  2. MANDALA M, Lorigan P, Sergi MC, Benannoune N, et al
    Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
    Eur J Cancer. 2024;199:113542.
    PubMed     Abstract available


  3. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
    Eur J Cancer. 2024;199:113531.
    PubMed     Abstract available


  4. LI Z, Song Y, Farrukh Hameed NU, Yuan S, et al
    Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
    Eur J Cancer. 2024;199:113528.
    PubMed     Abstract available


  5. HABRINGER S, Demel UM, Fietz AK, Lammer F, et al
    A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Eur J Cancer. 2024;196:113436.
    PubMed     Abstract available


  6. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    PubMed     Abstract available


    December 2023
  7. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
    Eur J Cancer. 2023;198:113475.
    PubMed     Abstract available


  8. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    PubMed     Abstract available


    September 2023
  9. ROSSIDES M, Mogensen H, Kampitsi CE, Talback M, et al
    Parental occupational exposure to metals and risk of cancer in the offspring: A register-based case-control study from Sweden.
    Eur J Cancer. 2023;191:113243.
    PubMed     Abstract available


    August 2023
  10. DOHM AE, Nakashima JY, Kalagotla H, Jiang SX, et al
    Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
    Eur J Cancer. 2023;192:113287.
    PubMed     Abstract available


  11. SOUSSAIN C, Malaise D, Choquet S, Ghesquieres H, et al
    Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral L
    Eur J Cancer. 2023;189:112909.
    PubMed    


    June 2023
  12. PADOVAN M, Maccari M, Bosio A, De Toni C, et al
    Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
    Eur J Cancer. 2023;191:112959.
    PubMed     Abstract available


  13. REIJNEVELD JC, Machingura A, Coens C, Taphoorn MJB, et al
    Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Trea
    Eur J Cancer. 2023;190:112946.
    PubMed     Abstract available


    May 2023
  14. DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al
    Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
    Eur J Cancer. 2023;187:161-163.
    PubMed    


  15. HERTLER C, Felsberg J, Gramatzki D, Le Rhun E, et al
    Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Eur J Cancer. 2023 May 8:S0959-8049(23)00230-7. doi: 10.1016/j.ejca.2023.
    PubMed     Abstract available


    April 2023
  16. ALAFANDI A, van Garderen KA, Klein S, van der Voort SR, et al
    Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
    Eur J Cancer. 2023;188:122-130.
    PubMed     Abstract available


  17. MANACORDA S, Carmena MT, Malone C, Linh Le HM, et al
    Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
    Eur J Cancer. 2023;188:98-107.
    PubMed     Abstract available


    March 2023
  18. CARAMANNA I, Reijneveld JC, van de Ven PM, van den Bent M, et al
    Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023;186:38-51.
    PubMed     Abstract available


    December 2022
  19. CHEN PC, Yeh YM, Chu CT, Su PF, et al
    HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
    Eur J Cancer. 2022;181:62-69.
    PubMed     Abstract available


    November 2022
  20. DI GIACOMO AM, Mair MJ, Ceccarelli M, Anichini A, et al
    Immunotherapy for brain metastases and primary brain tumors.
    Eur J Cancer. 2022;179:113-120.
    PubMed     Abstract available


  21. TESILEANU CMS, Vallentgoed WR, French PJ, van den Bent MJ, et al
    Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
    Eur J Cancer. 2022;175:214-223.
    PubMed     Abstract available


  22. TER MAAT LS, van Duin IAJ, Elias SG, van Diest PJ, et al
    Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review.
    Eur J Cancer. 2022;175:60-76.
    PubMed     Abstract available


  23. SERRA-BELLVER P, Versluis JM, Oberoi HK, Zhou C, et al
    Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
    Eur J Cancer. 2022;176:121-132.
    PubMed     Abstract available


    October 2022
  24. MUELLER T, Laternser S, Guerreiro Stucklin AS, Gerber NU, et al
    Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Eur J Cancer. 2022;178:171-179.
    PubMed     Abstract available


  25. WU F, Sun Y
    Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment.
    Eur J Cancer. 2022;178:34-36.
    PubMed    


  26. LE RHUN E, Oppong FB, van den Bent M, Wick W, et al
    Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    Eur J Cancer. 2022;178:13-22.
    PubMed     Abstract available


    September 2022
  27. DUTRIAUX C, Robert C, Grob JJ, Mortier L, et al
    An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
    Eur J Cancer. 2022;175:254-262.
    PubMed     Abstract available


  28. WANG Y, Lian B, Si L, Mao L, et al
    Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.
    Eur J Cancer. 2022;175:196-203.
    PubMed     Abstract available


  29. VOGLIS S, Schaller V, Muller T, Gonel M, et al
    Maximal surgical tumour load reduction in immune-checkpoint inhibitor naive patients with melanoma brain metastases correlates with prolonged survival.
    Eur J Cancer. 2022;175:158-168.
    PubMed     Abstract available


  30. TAIEB J, Svrcek M, Cohen R, Basile D, et al
    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Eur J Cancer. 2022;175:136-157.
    PubMed     Abstract available


  31. LV J, Chen S, Chen X, Xie J, et al
    Effect of glioma-derived immunoglobulin on biological function of glioma cells.
    Eur J Cancer. 2022;175:86-98.
    PubMed     Abstract available


    July 2022
  32. TAN DSW, Kim SW, Ponce Aix S, Sequist LV, et al
    Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
    Eur J Cancer. 2022;172:276-286.
    PubMed     Abstract available


    June 2022
  33. SCHUBERT NA, Chen CY, Rodriguez A, Koster J, et al
    Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
    Eur J Cancer. 2022;170:196-208.
    PubMed     Abstract available


    May 2022
  34. CHRISTOPOULOS P, Kluck K, Kirchner M, Luders H, et al
    The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
    Eur J Cancer. 2022;170:106-118.
    PubMed     Abstract available


  35. KREFT S, Glutsch V, Zaremba A, Schummer P, et al
    MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Eur J Cancer. 2022;167:32-41.
    PubMed     Abstract available


    February 2022
  36. HAGEL C, Sloman V, Mynarek M, Petrasch K, et al
    Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial.
    Eur J Cancer. 2022;164:30-38.
    PubMed     Abstract available


  37. KELLER KM, Krausert S, Gopisetty A, Luedtke D, et al
    Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.
    Eur J Cancer. 2022;162:107-117.
    PubMed     Abstract available


    January 2022
  38. BALDINI C, Younan N, Castanon Alvarez E, Ammari S, et al
    Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
    Eur J Cancer. 2022;163:98-107.
    PubMed     Abstract available


  39. SKAYEM C, Garcia G, Grill J, Aghakhani N, et al
    First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.
    Eur J Cancer. 2022;162:206-208.
    PubMed    


  40. STEINDL A, Brunner TJ, Heimbach K, Schweighart K, et al
    Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
    Eur J Cancer. 2022;162:170-181.
    PubMed     Abstract available


    November 2021
  41. VASSELLA E, Kashani E, Zens P, Kundig A, et al
    Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
    Eur J Cancer. 2021;159:227-236.
    PubMed     Abstract available


  42. SCHULPEN M, Visser O, Reedijk AMJ, Kremer LCM, et al
    Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s.
    Eur J Cancer. 2021;157:81-93.
    PubMed     Abstract available


    October 2021
  43. KARSCHNIA P, Le Rhun E, Vogelbaum MA, van den Bent M, et al
    The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy.
    Eur J Cancer. 2021;156:93-108.
    PubMed     Abstract available


    August 2021
  44. GKEKAS I, Novotny J, Kaprio T, Beilmann-Lehtonen I, et al
    Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases.
    Eur J Cancer. 2021;157:1-9.
    PubMed     Abstract available


  45. HILBERS ML, Dimitriou F, Lau P, Bhave P, et al
    Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Eur J Cancer. 2021;156:149-163.
    PubMed     Abstract available


  46. LOMBARDI G, Del Bianco P, Brandes AA, Eoli M, et al
    Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Eur J Cancer. 2021;155:179-190.
    PubMed     Abstract available


    July 2021
  47. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    PubMed     Abstract available


    May 2021
  48. CHORTI E, Kebir S, Ahmed MS, Keyvani K, et al
    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Eur J Cancer. 2021;148:395-404.
    PubMed     Abstract available


    April 2021
  49. VERBRUGGEN LC, Kok JL, Teepen JC, Janssens GO, et al
    Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study.
    Eur J Cancer. 2021;150:240-249.
    PubMed     Abstract available


  50. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    PubMed     Abstract available


  51. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    PubMed     Abstract available


  52. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    PubMed     Abstract available


    March 2021
  53. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    PubMed     Abstract available


    February 2021
  54. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    PubMed     Abstract available


  55. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    PubMed     Abstract available


  56. BERLANGA P, Pasqualini C, Potschger U, Sanguesa C, et al
    Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Eur J Cancer. 2021;144:1-8.
    PubMed     Abstract available


    January 2021
  57. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    PubMed     Abstract available


    December 2020
  58. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    PubMed     Abstract available


    November 2020
  59. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    PubMed     Abstract available


    October 2020
  60. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    PubMed     Abstract available


    September 2020
  61. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    PubMed     Abstract available


    July 2020
  62. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    PubMed     Abstract available


    April 2020
  63. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available


    March 2020
  64. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.